Lupin is currently trading at Rs. 1466.85, up by 2.25 points or 0.15% from its previous closing of Rs. 1464.60 on the BSE.
The scrip opened at Rs. 1472.00 and has touched a high and low of Rs. 1478.95 and Rs. 1463.65 respectively. So far 36182 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1876.00 on 11-Feb-2016 and a 52 week low of Rs. 1294.05 on 29-Mar-2016.
Last one week high and low of the scrip stood at Rs. 1572.25 and Rs. 1459.95 respectively. The current market cap of the company is Rs. 66186.96 crore.
The promoters holding in the company stood at 46.71%, while institutions and non-institutions held 41.46% and 11.83% respectively.
Lupin is planning to launch around 25 products in the US in next finance year. The drug major’s focus remains on the speciality drugs business in the US.
The Mumbai-based drug firm launched four products in the US market during the third quarter ended December 31. It received 11 approvals from the USFDA during the period. It now has a portfolio of 128 generic products in the US market.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.